EONE DIAGNOMICS GENOME CENTER CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 415 KRW | -5.25% |
|
-.--% | -0.72% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 188,823 | 193,525 | 385,599 | 265,207 | 156,851 | 48,877 |
| Enterprise Value (EV) 1 | 171,695 | 202,298 | 378,883 | 320,417 | 235,102 | 110,162 |
| P/E ratio | -22.3 x | -22.5 x | -35.7 x | -12.8 x | -5.15 x | -1.14 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 8.78 x | 3.41 x | 4.17 x | 2.97 x | 1.66 x | 0.55 x |
| EV / Revenue | 7.99 x | 3.57 x | 4.09 x | 3.59 x | 2.49 x | 1.25 x |
| EV / EBITDA | -27.5 x | -32.4 x | -376 x | -31.6 x | -66.3 x | -29.4 x |
| EV / FCF | -19.5 x | -12.5 x | 146 x | -18.7 x | -4.63 x | -6.79 x |
| FCF Yield | -5.13% | -8.03% | 0.69% | -5.35% | -21.6% | -14.7% |
| Price to Book | 4.14 x | 4.8 x | 5.51 x | 4.56 x | 4.82 x | 1.19 x |
| Nbr of stocks (in thousands) | 72,346 | 72,346 | 81,179 | 81,602 | 83,877 | 116,931 |
| Reference price 2 | 2,610 | 2,675 | 4,750 | 3,250 | 1,870 | 418.0 |
| Announcement Date | 3/21/19 | 3/19/20 | 3/23/21 | 3/18/22 | 3/21/23 | 4/8/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 21,497 | 56,722 | 92,541 | 89,282 | 94,244 | 88,457 |
| EBITDA 1 | -6,246 | -6,249 | -1,008 | -10,141 | -3,545 | -3,745 |
| EBIT 1 | -6,815 | -8,582 | -5,109 | -15,731 | -9,720 | -10,014 |
| Operating Margin | -31.7% | -15.13% | -5.52% | -17.62% | -10.31% | -11.32% |
| Earnings before Tax (EBT) 1 | -7,045 | -8,211 | -8,172 | -20,229 | -29,789 | -34,088 |
| Net income 1 | -7,602 | -9,802 | -10,398 | -20,667 | -29,865 | -33,027 |
| Net margin | -35.36% | -17.28% | -11.24% | -23.15% | -31.69% | -37.34% |
| EPS 2 | -116.8 | -118.9 | -133.0 | -254.0 | -363.0 | -367.0 |
| Free Cash Flow 1 | -8,813 | -16,236 | 2,601 | -17,138 | -50,749 | -16,229 |
| FCF margin | -41% | -28.62% | 2.81% | -19.19% | -53.85% | -18.35% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/21/19 | 3/19/20 | 3/23/21 | 3/18/22 | 3/21/23 | 4/8/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 8,772 | - | 55,210 | 78,252 | 61,285 |
| Net Cash position 1 | 17,128 | - | 6,716 | - | - | - |
| Leverage (Debt/EBITDA) | - | -1.404 x | - | -5.444 x | -22.07 x | -16.36 x |
| Free Cash Flow 1 | -8,813 | -16,236 | 2,601 | -17,138 | -50,749 | -16,229 |
| ROE (net income / shareholders' equity) | -23.3% | -17.3% | -16% | -32% | -49.6% | -50.7% |
| ROA (Net income/ Total Assets) | -9.59% | -6.25% | -2.49% | -5.66% | -3.21% | -3.42% |
| Assets 1 | 79,286 | 156,716 | 418,000 | 364,956 | 931,469 | 964,475 |
| Book Value Per Share 2 | 630.0 | 557.0 | 862.0 | 712.0 | 388.0 | 353.0 |
| Cash Flow per Share 2 | 253.0 | 253.0 | 747.0 | 337.0 | 56.90 | 87.10 |
| Capex 1 | 1,163 | 7,018 | 3,431 | 13,711 | 39,231 | 5,697 |
| Capex / Sales | 5.41% | 12.37% | 3.71% | 15.36% | 41.63% | 6.44% |
| Announcement Date | 3/21/19 | 3/19/20 | 3/23/21 | 3/18/22 | 3/21/23 | 4/8/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -0.72% | 41.47M | |
| +16.03% | 70.59B | |
| +2.22% | 25.06B | |
| +7.11% | 8.2B | |
| -2.98% | 7.92B | |
| -20.55% | 7.96B | |
| +3.91% | 4.71B | |
| +17.12% | 4.32B | |
| -1.24% | 4.01B | |
| -3.44% | 3.82B |
- Stock Market
- Equities
- A245620 Stock
- Financials Eone Diagnomics Genome Center Co., Ltd.
